An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)

Part of paid clinical trials in Mobile, Alabama.

Sponsor
GlaxoSmithKline
Study ID
NCT05243680
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
12 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this open-label 12-month extension study is to continue to characterize the long-term safety, efficacy and immunogenic profile of GSK3511294 (Depemokimab) in participants with severe asthma with an eosinophilic phenotype following completion of clinical studies 206713 or 213744.

Key Dates

Start date
Mar 1, 2022
Status verified
Dec 2025
Primary completion
May 19, 2025
Completion
May 19, 2025

Study Design

Enrollment
641 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Participants diagnosed with asthma receiving GSK3511294 (Depemokimab)

Primary Outcome Measure

Number of Participants With Any Adverse Events (AEs) and Serious AEs (SAEs) [ Time Frame: Up to Week 56 ]

Locations (29)

FacilityCityStateZIPSite coordinators
GSK Investigational SiteMobileAlabama36608-
GSK Investigational SiteLancasterCalifornia93534-
GSK Investigational SiteColorado SpringsColorado80923-
GSK Investigational SiteLafayetteColorado80026-
GSK Investigational SiteCoral GablesFlorida33134-
GSK Investigational SiteHialeahFlorida33013-
GSK Investigational SiteLoxahatchee GrovesFlorida33470-
GSK Investigational SiteMiamiFlorida33144-
GSK Investigational SiteMiamiFlorida33173-
GSK Investigational SiteMiamiFlorida33186-
GSK Investigational SiteOrlandoFlorida32806-
GSK Investigational SiteSavannahGeorgia31406-
GSK Investigational SiteNormalIllinois61761-
GSK Investigational SiteLexingtonKentucky40509-
GSK Investigational SiteYpsilantiMichigan48197-
GSK Investigational SiteNorthfieldNew Jersey08225-
GSK Investigational SiteToms RiverNew Jersey08755-
GSK Investigational SiteThe BronxNew York10461-
GSK Investigational SiteGastoniaNorth Carolina28054-
GSK Investigational SiteHuntersvilleNorth Carolina28078-
GSK Investigational SiteWinston-SalemNorth Carolina27103-
GSK Investigational SiteDuBoisPennsylvania15801-
GSK Investigational SiteAllenTexas75013-
GSK Investigational SiteBoerneTexas78006-
GSK Investigational SiteDallasTexas75225-
GSK Investigational SiteKerrvilleTexas78028-
GSK Investigational SiteSan AntonioTexas78207-
GSK Investigational SiteSan AntonioTexas78229-
GSK Investigational SiteBellinghamWashington98225-

Related coverage on Hipa.ai

Find similar trials in Mobile, AL

By condition
Asthma
By specialty
PulmonologyLung disease
By research site
GSK Investigational Site· Mobile, ALGSK Investigational Site· Lancaster, CAGSK Investigational Site· Colorado Springs, COGSK Investigational Site· Lafayette, COGSK Investigational Site· Coral Gables, FLGSK Investigational Site· Hialeah, FL

Related Studies